{"id":"NCT02436239","sponsor":"Forest Laboratories","briefTitle":"A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder","officialTitle":"An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-02","primaryCompletion":"2018-07-23","completion":"2018-07-23","firstPosted":"2015-05-06","resultsPosted":"2019-09-11","lastUpdate":"2019-09-11"},"enrollment":330,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Vilazodone","otherNames":["Viibryd"]}],"arms":[{"label":"Vilazodone","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).","primaryOutcome":{"measure":"Number of Participants to Experience a Treatment Emergent Adverse Event (TEAE)","timeFrame":"Visit 1 (Week -1) to up to Visit 16 (Week 26)","effectByArm":[{"arm":"Placebo/Vilazodone","deltaMin":90,"sd":null},{"arm":"Vilazodone/Vilazodone","deltaMin":89,"sd":null},{"arm":"Fluoxetine/Vilazodone","deltaMin":48,"sd":null},{"arm":"De Novo/Vilazodone","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":56,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":122},"commonTop":["Headache","Nausea","Weight increased","Vomiting","Insomnia"]}}